Aurobindo Pharma Ltd

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Aurobindo Pharma Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24239TG1986PLC015190</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>1170.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>AA+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>INDIA RATINGS AND RESEARCH PVT. LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: B ADI REDDY <br/> Designation: Company Secretary <br/> EmailId: cs@aurobindo.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: SANTHANAM SUBRAMANIAN <br/> Designation: Chief Financial Officer <br/> EmailId: subramanian.santhanam@auroindo.com</div> </div> <div> <br/> Date: 28/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

Intimation of fire accident at Lyfius Pharma Private Limited a wholly owned step down subsidiary of the Company.